Brokerages expect that Marrone Bio Innovations Inc (NASDAQ:MBII) will report earnings per share (EPS) of ($0.04) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Marrone Bio Innovations’ earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.04). Marrone Bio Innovations also reported earnings per share of ($0.04) in the same quarter last year. The business is expected to report its next quarterly earnings results after the market closes on Thursday, May 9th.
According to Zacks, analysts expect that Marrone Bio Innovations will report full year earnings of ($0.17) per share for the current fiscal year, with EPS estimates ranging from ($0.20) to ($0.15). For the next year, analysts anticipate that the business will post earnings of ($0.14) per share, with EPS estimates ranging from ($0.16) to ($0.11). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Marrone Bio Innovations.
Marrone Bio Innovations (NASDAQ:MBII) last released its quarterly earnings data on Thursday, March 14th. The basic materials company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). Marrone Bio Innovations had a negative return on equity of 110.20% and a negative net margin of 95.26%. The business had revenue of $5.72 million for the quarter, compared to analyst estimates of $5.03 million.
Separately, National Securities reiterated a “buy” rating and set a $2.50 target price on shares of Marrone Bio Innovations in a research report on Thursday, April 25th.
Marrone Bio Innovations stock traded up $0.01 during mid-day trading on Friday, hitting $1.56. The company had a trading volume of 101 shares, compared to its average volume of 107,852. The company has a current ratio of 2.66, a quick ratio of 1.94 and a debt-to-equity ratio of 1.48. Marrone Bio Innovations has a 12-month low of $1.10 and a 12-month high of $2.18. The firm has a market cap of $172.71 million, a PE ratio of -7.38 and a beta of -0.12.
In other news, major shareholder Van Herk Investments B.V. sold 1,500,000 shares of the stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $1.57, for a total transaction of $2,355,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.90% of the company’s stock.
Several large investors have recently made changes to their positions in MBII. BlackRock Inc. raised its position in shares of Marrone Bio Innovations by 3.4% during the 3rd quarter. BlackRock Inc. now owns 2,786,505 shares of the basic materials company’s stock worth $5,099,000 after acquiring an additional 92,454 shares in the last quarter. Vanguard Group Inc. increased its stake in Marrone Bio Innovations by 13.5% during the third quarter. Vanguard Group Inc. now owns 2,554,605 shares of the basic materials company’s stock worth $4,675,000 after acquiring an additional 303,201 shares during the last quarter. Vanguard Group Inc increased its stake in Marrone Bio Innovations by 13.5% during the third quarter. Vanguard Group Inc now owns 2,554,605 shares of the basic materials company’s stock worth $4,675,000 after acquiring an additional 303,201 shares during the last quarter. Rhumbline Advisers increased its stake in Marrone Bio Innovations by 44.3% during the fourth quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock worth $100,000 after acquiring an additional 20,882 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Marrone Bio Innovations by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock worth $652,000 after acquiring an additional 24,460 shares during the last quarter. Hedge funds and other institutional investors own 42.14% of the company’s stock.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
See Also: How to Invest in a Bull Market
Get a free copy of the Zacks research report on Marrone Bio Innovations (MBII)
For more information about research offerings from Zacks Investment Research, visit Zacks.com